Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.77 |
| ▸ | ITGAV | P06756 | 5/20 | 0.77 |
| ▸ | NCF1 | P14598 | 9/20 | 0.40 |
| ▸ | CYBB | P04839 | 1/20 | 0.40 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21479481 | 0.95 | ITGB3 (0.70) | ITGB3ITGAVNCF1CYBBNOX5 | |
| SCHEMBL21100942 | 0.95 | ITGB3 (0.70) | ITGB3ITGAVNCF1CYBBNOX5 | |
| SCHEMBL29107238 | 0.89 | ITGB3 (0.61) | ITGB3ITGAVFOLH1 | |
| SCHEMBL23868262 | 0.87 | ITGB3 (0.71) | ITGB3ITGAVABCG2MMP2MMP9 | |
| SCHEMBL21100766 | 0.83 | ITGB3 (0.64) | ITGB3ITGAVABCG2 | |
| SCHEMBL19677591 | 0.82 | ITGB3 (0.71) | ITGB3ITGAVNCF1CYBBNOX5 | |
| SCHEMBL21100765 | 0.80 | ITGB3 (0.60) | ITGB3ITGAVNCF1ABCG2 | |
| SCHEMBL21475355 | 0.80 | ITGB3 (0.60) | ITGB3ITGAVNCF1ABCG2 | |
| SCHEMBL21100868 | 0.79 | ITGB3 (0.55) | ITGB3ITGAV | |
| SCHEMBL21101049 | 0.79 | ITGB3 (0.54) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773540-B1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3773540-B1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4351650-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NanoPharmaceuticals LLC (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260918-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3773540-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NanoPharmaceuticals LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019199532-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC | 2019-10-17 | — | — | US | disclosed |
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC | 2019-10-17 | — | — | US | disclosed |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885NCF1 1884/4885 |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885NCF1 1884/4885 |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885NCF1 1884/4885 |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885NCF1 1884/4885 |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885NCF1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.